Cancer Immunotherapy Race Stays Unpredictable
Merck, Bristol-Myers and Roche head the race to pioneer PD-1 therapies.
Can Bristol-Myers Squibb Keep Its Bull Run Going in 2014?
The year 2013 was a great one for Bristol-Myers Squibb (NYSE: BMY); 2014 could also be a strong year due to a potential catalyst.
Why Sangamo Biosciences, Inc. Trounced the Market
Sangamo Biosciences shot up 20% today, but this may still be one to watch at a distance.
Bristol-Myers Squibb's Blockbuster Immunotherapy Opportunity
Recently published long-term survival data for nivolumab is so promising that short term concerns seem trivial.
Why Sangamo Biosciences Inc. Shares Surged
Sangamo shares soared after it released intriguing clinical data in its attempt to treat HIV. Should shareholders be excited or cautious regarding Sangamo's move higher?
AbbVie Inc. Aces Its Hep C Trial, but Is It Too Late?
AbbVie's (ABBV) phase 3 trial data is compelling; however that doesn't guarantee it will win out over competitors Gilead (GILD) and Bristol-Myers (BMY)
3 Stocks to Get on Your Watchlist
Global pharma giant Pfizer, small-cap oil and gas exploration and production company Midstates Petroleum, and potentially overvalued online community Yelp are today's three must-watch stocks.
FDA Rejects Eli Lilly's Diabetes Drug Empagliflozin
If approved, empagliflozin from Eli Lilly and Boehringer Ingelheim Pharmaceuticals would compete against AstraZeneca's Forxiga and Johnson & Johnson's Invokana.
Can Pfizer Overcome Its Patent Woes?
With patent expiry causing pressure on sales, Pfizer (NYSE: PFE) is attempting an alternative response.